Introduction: One of the most relevant focus of recent developments in radiotherapy technology was the adequate irradiation of prostate cancer. Aim: The aim of this study was to analyse the safety of normo- and hypofractionated and high dose intensity-modulated radiotherapy. Method: Toxicities were identified through literature review and evidence was synthetized with meta-analytical methods. Results: The use of high dose intensity-modulated radiotherapy resulted in no difference in severe genitourinary (acute p = 0.9; late p = 0.95) and moderate or severe gastrointestinal (acute: N/A; late: p = 0.08) toxicities compared to 3D conformal radiation therapy. The risk ratio of moderate acute (RR = 1.39, 95% CI: 1.09–1.78; p = 0.008) and late genitourinary toxicities (RR = 1.48, 95% CI: 1.26–1.75; p<0,00001) was higher. There was no difference in hypo- and normofractionated intensity-modulated radiotherapy regarding severe genitourinary (acute: N/A; late: p = 0.73) and moderate or severe gastrointestinal (acute: p = 0.73; late: p = 0.55) toxicities, the risk of late moderate genitourinary toxicities was higher when using hypofractionation scheme (RR = 1.39, 95% CI: 1.00–1.94; p = 0.05). Conclusions: The use of normo- and hypofractionated and high dose intensity-modulated radiotherapy proved to be safe. However the higher risk of moderate genitourinary adverse events require an extensive clinical risk estimation. Orv. Hetil., 2016, 157(20), 776–788.
High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients
